A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Bimagrumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 15 Nov 2017 Planned End Date changed from 3 Jan 2019 to 2 Aug 2019.
- 15 Nov 2017 Planned primary completion date changed from 3 Jan 2019 to 7 Jun 2019.
- 10 Jun 2017 Biomarkers information updated